Encompass Health Announces Date of 2026 Third-quarter Earnings Call
Encompass Health (NYSE: EHC) will release its 2026 third-quarter earnings on October 25, 2026, after the market closes. The company will host an investor conference call the following morning, October 26, 2026, at 9:00 a.m. ET to discuss the results.
Encompass Health announces date of 2026 third-quarter earnings call
Encompass Health Corp. (NYSE: EHC) has announced that it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will host an investor conference call at 10 a.m. ET on Thursday, October 29, 2026, to discuss these results. Interested parties can access the call via phone or live webcast on the company's investor website.
Third-quarter results are due Oct. 28; Encompass Health's call follows the next morning.
Encompass Health (NYSE: EHC) has scheduled its third-quarter 2026 earnings release for after market close on October 28, 2026. The company will host an investor conference call on October 29, 2026, at 10 a.m. ET to discuss the results. A live webcast and online replay of the call will be available on Encompass Health's investor website.
Encompass Health announces date of 2026 third-quarter earnings call
Encompass Health Corp. (NYSE: EHC) announced it will release its third-quarter 2026 financial results after market close on Wednesday, October 28, 2026. The company will host an investor conference call at 10 a.m. ET on Thursday, October 29, 2026, to discuss these results. Interested parties can access the call via a provided dial-in number and conference ID, or through a live webcast on the company's investor website.
If You Invested $100 In Encompass Health Stock 15 Years Ago, You Would Have This Much Today
Encompass Health (NYSE: EHC) has significantly outperformed the market over the last 15 years, achieving an average annual return of 16.76%. An initial investment of $100 in EHC stock 15 years ago would now be worth $1,033.83. This highlights the substantial impact of compounded returns on investment growth over time.
Raymond James assumes coverage on Encompass Health stock with Strong Buy rating
Raymond James initiated coverage on Encompass Health Corp (NYSE:EHC) with a Strong Buy rating and a price target of $150.00, suggesting a potential upside of approximately 21%. The firm views Encompass Health as a compelling opportunity in healthcare, noting its strong positioning in inpatient rehabilitation despite trading at a relatively higher multiple. Recent financial results show the company exceeding earnings and revenue forecasts, further supporting the optimistic outlook.
EHC4882391 Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for Encompass Health Corporation's EHC4882391 bond, highlighting its coupon and redemption information. It covers key facts such as the issuer, issue and maturity dates, face value, and minimum denomination, alongside details on its fixed semi-annual coupon rate of 4.50%. The profile also includes an upcoming payout schedule and the outstanding amount of the bond.
Encompass Health plans two hospitals in Montgomery County, Texas By Investing.com
Encompass Health Corp. (NYSE:EHC) announced plans to expand its inpatient rehabilitation capacity in the greater Houston area with two new projects in Montgomery County, Texas. These include a 24-bed small-format inpatient rehabilitation hospital in Conroe, expected in late 2027, and a 60-bed replacement hospital on The Woodlands campus, slated for 2029. These facilities aim to provide comprehensive rehabilitation care for various conditions.
Encompass Health expands in Montgomery County, Texas, with first small-format hospital, replacement hospital
Encompass Health Corp. is expanding its inpatient rehabilitation capacity in Montgomery County, Texas, with two new projects. These include the company's first small-format inpatient rehabilitation hospital in Conroe, expected to open in late 2027, and a 60-bed replacement hospital on the existing Woodlands campus, slated for 2029. These initiatives aim to increase access to specialized rehabilitation care and enhance the patient experience in the greater Houston area.
Encompass Health plans Conroe rehab hospital in master-planned community, filing shows
Encompass Health is planning to build a rehabilitation hospital in Conroe, expanding its presence in the Houston area. The Birmingham, Alabama-based company is a major inpatient rehabilitation service provider nationally. This new facility will be located within a master-planned community.
A new 50-bed rehabilitation hospital is taking patients in Pennsylvania
Encompass Health has opened its 11th location in Pennsylvania, a 50-bed inpatient rehabilitation hospital in Lower Providence Township, Montgomery County. This new facility offers intensive physical, occupational, and speech therapy, along with 24-hour nursing care, for patients recovering from various conditions such as strokes, brain injuries, and amputations. The hospital is designed to help patients regain functional ability, independence, and quality of life through personalized treatment plans and advanced amenities.
Encompass Health Rehabilitation Hospital of Lower Providence now open in Pennsylvania
Encompass Health has opened its 11th Pennsylvania location, the Encompass Health Rehabilitation Hospital of Lower Providence, a 50-bed inpatient facility in Montgomery County. The hospital offers specialized rehabilitation for conditions like strokes and brain injuries, providing intensive therapy and 24-hour nursing care. This new hospital expands access to high-quality rehabilitative services in the region, aiming to help patients regain independence and improve their quality of life.
Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?
Encompass Health (EHC) shares have declined 1.8% since its last earnings report, underperforming the S&P 500 despite beating Q2 earnings estimates and raising its 2026 outlook. The company reported strong revenue growth driven by increased patient revenue per discharge and discharge volumes, though higher operating expenses partly offset these gains. EHC's financial position remains strong, with increased cash and assets, and management reaffirmed growth targets for 2023-2027.
Encompass Health (NYSE: EHC) lines up flexible funding
Encompass Health (NYSE: EHC) has filed an automatic shelf registration statement on Form S-3, providing flexibility to offer various securities like common stock, preferred stock, warrants, and debt securities for general corporate purposes. The company, a leading operator of inpatient rehabilitation hospitals, reported $2.065.1 million in net operating revenues and $229.1 million in net income for the first half of 2026. This filing allows for future capital raising without immediately specifying amounts or prices, with potential uses including debt repayment, share repurchases, and acquisitions.
Encompass Health Executive Sells Shares Amid Positive Earnings
John Patrick Darby, EVP and General Counsel of Encompass Health, sold 8,906 shares for $1.1 million, reducing his direct holdings to 75,041 shares. Despite this insider selling, which could suggest a decline in confidence, the company reported strong financial performance with $12.5 billion market capitalization and $6.2 billion in revenues. Encompass Health is also expected to benefit from a 2.3% increase in Medicare payments starting October, supporting long-term growth.
Encompass Health CEO Sells 173,000 Shares of Stock
Encompass Health CEO Mark J. Tarr sold 173,148 shares of common stock for $21.7 million on August 10, 2026, yet still retains a significant stake worth over $33.69 million, signaling continued confidence in the company despite the sale. The company, a leader in post-acute healthcare with a $12.5 billion market capitalization, recently reported a 10% revenue increase and raised its full-year guidance, reflecting strong growth and market confidence. Analyst ratings remain positive with increased price targets, further reinforcing the company's optimistic outlook.
Encompass Health CFO Sells Shares Amid Strong Performance
Encompass Health's CFO, Douglas E. Coltharp, sold 18,869 shares for $2.4 million on August 10, a modest reduction that still leaves him with significant indirect holdings, reflecting ongoing confidence in the company. The company is demonstrating strong market performance with a $12.5 billion market cap, $6.2 billion in trailing twelve-month revenues, and raised full-year guidance for the second time this year. Analysts forecast the stock price to rise, with Truist and Raymond James maintaining "Buy" and "Strong Buy" ratings, respectively, and increasing their price targets due to strong Q2 performance and positive industry dynamics.
T. Rowe Price Associates (EHC) discloses 5.1% Encompass Health stake on Schedule 13G
T. Rowe Price Associates has filed a Schedule 13G, disclosing a 5.1% beneficial ownership stake in Encompass Health Corp (EHC), totaling 5,056,225 common stock shares. The filing indicates that T. Rowe Price Associates holds sole voting power over 4,897,333 shares and sole dispositive power over all 5,056,225 shares. Importantly, the firm explicitly denies beneficial ownership of these securities, stating the filing should not be construed as an admission.
Form 8K Encompass Health Corp For: 13 August By Investing.com
This article announces that Encompass Health Corp filed a Form 8K on August 13. The brief notice from Investing.com is part of a larger financial news platform providing market data and company filings.
Form 8K Encompass Health Corp For: 13 August By Investing.com
This article reports on the filing of a Form 8K by Encompass Health Corp on August 13. The brief notice from Investing.com indicates this as a stock market event without providing further details on the content of the filing.
Encompass Health completes $100 million senior notes offering to repay debt
Encompass Health Corporation has successfully issued $100 million in 5.875% Senior Notes due 2034, generating net proceeds of approximately $96.9 million. These proceeds, along with existing cash, were used to repay a portion of its revolving credit facility. The company recently reported strong second-quarter 2026 results, exceeding Wall Street expectations for both EPS and revenue, and has raised its financial outlook.
Encompass Health issues $100M of 5.875% senior notes due 2034, nets ~$96.9M
Encompass Health (EHC) has completed a private issuance of $100 million in 5.875% Senior Notes due 2034, generating approximately $96.9 million after discounts and expenses. The proceeds, along with cash on hand, were utilized to reduce short-term borrowings by repaying a portion of the company's revolving credit facility. These new notes share identical terms with existing 2034 notes and were sold to qualified institutional buyers and non-U.S. persons.
Encompass Health Corporation (EHC) Stock forecasts
This article provides stock forecast information for Encompass Health Corporation (EHC), noting that Argus has raised its target price for EHC to $138.00. The company's current price is $123.78, and it operates in the healthcare sector, providing post-acute healthcare services.
Encompass Health Corporation Completes Issuance and Sale of $100 Million 5.875% Senior Notes Due 2034
Encompass Health Corporation has completed the issuance and sale of an additional $100 million in 5.875% Senior Notes due 2034 through a private offering, generating approximately $96.9 million in net proceeds. These proceeds, combined with cash on hand, were used to repay a portion of the company's outstanding revolving credit facility. The newly issued notes have identical terms to existing notes issued in May 2026 and are treated as a single class under the indenture.
Encompass Health announces launch of private offering of 5.875% senior notes due 2034
Encompass Health Corp. announced a private offering of an additional $100 million in 5.875% senior notes due 2034. These "Additional Notes" will reopen the existing 2034 senior notes and will be guaranteed by the company's subsidiaries. The net proceeds from this offering, combined with cash on hand, will be used to repay outstanding amounts under the company's senior secured revolving credit facility.
EHC6480675 Bond Price and Chart — FINRA:EHC6480675
This article provides details on the EHC6480675 bond, issued by Encompass Health Corporation. It includes key terms such as a 5.88% coupon and a maturity date of June 1, 2034, along with issuer information, sector, industry, and various identifiers. The bond currently shows no trades as the market is closed.
Encompass Health (EHC) President & CEO Mark Tarr Sells 173,148 Shares
Mark Tarr, President and CEO of Encompass Health Corp (EHC), sold 173,148 shares of the company on August 10, 2026, marking a significant reduction in his direct holdings. This transaction is part of a broader trend of insider selling at EHC, with no insider buys in the past year against nine insider sells. Despite the insider selling, the stock is considered "Fairly Valued" by the GuruFocus GF Value at $114.25, with shares trading at $125.47, and guru ownership shows mixed activity.
Encompass Health EVP, general counsel John Darby sells $1.12 million in stock
John Patrick Darby, Executive Vice President, General Counsel, and Secretary of Encompass Health Corp (NYSE:EHC), sold 8,906 shares of the company’s common stock for approximately $1.12 million. The sale occurred on August 10, 2026, with shares trading near their 52-week high after a 14% gain. Following the transactions, Mr. Darby directly holds 75,041 shares of Encompass Health common stock.
Encompass Health president & CEO Mark Tarr sells $21.7m in stock
Mark J. Tarr, President and CEO of Encompass Health Corp (NYSE:EHC), sold 173,148 shares of the company’s common stock for approximately $21.7 million on August 10, 2026. Following these transactions, Mr. Tarr directly owns 267,814 shares. The sale occurred as EHC trades near its 52-week high, and comes shortly after the company reported strong Q2 2026 financial results, surpassing expectations and raising its financial outlook.
Encompass Health (EHC) EVP John Patrick Darby sells 8,906 shares in August trade
John Patrick Darby, EVP, General Counsel & Secretary of Encompass Health Corp (EHC), sold 8,906 shares of common stock on August 10, 2026. The shares were sold at a weighted average price of $125.95, totaling approximately $1.12 million. Following this transaction, Darby directly holds 75,041 shares of Encompass Health.
Encompass Health (EHC) CEO Mark Tarr sells 173,148 shares in open-market trades
Encompass Health's President & CEO, Mark J. Tarr, sold a total of 173,148 shares of the company's common stock in two open-market transactions on August 10, 2026. The sales were executed at weighted average prices of $125.46 and $126.06 per share, respectively, totaling over $21.7 million. These transactions, reported via a Form 4 filing, indicate a "Very Negative" sentiment due to the significant insider selling.
Pacer Advisors Inc. Reduces Stock Position in Encompass Health Corporation $EHC
Pacer Advisors Inc. significantly reduced its stake in Encompass Health Corporation by 93.1% in the first quarter, selling over 160,000 shares but still retaining a holding worth approximately $1.16 million. Despite this reduction and some recent analyst downgrades, Encompass Health maintains a "Moderate Buy" consensus rating and has exceeded its latest quarterly earnings and revenue expectations. The company also raised its quarterly dividend, signaling continued financial health and positive outlook.
Encompass Health Prices $100M 5.875% Notes Due 2034 | EHC Stock News
Encompass Health (NYSE: EHC) announced the pricing of a private offering of an additional $100 million in aggregate principal amount of its 5.875% senior notes due 2034. These "Additional Notes" will reopen the existing 2034 series and carry the same terms, priced at 98.75% of principal. The company intends to use the net proceeds, along with cash on hand, to repay outstanding amounts under its senior secured revolving credit facility, with the offering expected to close on August 13, 2026.
Encompass Health (EHC) insider plans sale of 18,869 vested RSA shares
An insider at Encompass Health Corporation, Douglas Coltharp, has filed a Form 144 to sell 18,869 shares of common stock, valued at approximately $2.36 million. The proposed sale is linked to restricted stock award vesting events from early 2025. Coltharp had previously sold 27,694 shares of EHC stock in May 2026 for about $2.96 million.
Encompass Health Prices $100 Million Add-On Senior Notes at 1.25% Discount to Par
Encompass Health Corp. (EHC) announced the pricing of an additional $100 million of its 5.875% Senior Notes due 2034, issued at a 1.25% discount to par. This tap offering will fund the repayment of borrowings under the company's revolving credit facility. The private placement is expected to settle on August 13, 2026, and carries identical terms to notes initially issued in May 2026.
Encompass Health Corp SEC Filing (Aug 10, 2026)
This article reports on an SEC Form 144 filing by Encompass Health Corp (EHC) on August 10, 2026. The filing indicates a proposed sale of 173,148 shares of common stock with an aggregate market value of $21,722,174.82 by an individual who acquired the shares through an equity plan in 2022. The sale is being handled by UBS Financial Services Inc.
Encompass Health prices private offering of additional 5.875% senior notes due 2034
Encompass Health Corp. announced the pricing of a private offering for an additional $100 million in 5.875% senior notes due 2034, which will be treated as the same class as previously issued notes. The company plans to use the net proceeds, along with cash on hand, to repay outstanding amounts under its senior secured revolving credit facility. The offering is expected to close on August 13, 2026, and was made to qualified institutional buyers and certain non-U.S. persons.
Encompass Health Intends to Use $100M Offering to Repay Debt
Encompass Health (NYSE: EHC) has launched a private offering of an additional $100 million in 5.875% senior notes due 2034. These notes will supplement an existing series and are intended to repay outstanding amounts under the company's senior secured revolving credit facility, effectively refinancing existing borrowings. The offering is a private placement under Rule 144A and Regulation S, not registered under the Securities Act.
Encompass Health announces launch of private offering of 5.875% senior notes due 2034
Encompass Health Corp. has announced a private offering of an additional $100 million in 5.875% senior notes due in 2034. These Additional Notes will be part of the same class as the Existing Notes issued in May 2026 and will be guaranteed by the Company's subsidiaries. The net proceeds from this offering, combined with cash on hand, will be used to repay outstanding amounts under the Company's senior secured revolving credit facility.
Encompass Health Corp. Announces Launch Of Private Offering Of $100 Million 5.875% Senior Notes Due 2034
Encompass Health Corp. has launched a private offering for an additional $100 million of 5.875% senior notes due in 2034. These new notes will be part of the same class as previously issued notes from May 2026 and will be guaranteed by the company's subsidiaries. The proceeds from this offering, combined with cash on hand, will be used to repay outstanding amounts on their senior secured revolving credit facility.
ENCOMPASS HEALTH CORP : TD COWEN RAISES TARGET PRICE TO $140 FROM $125
TD Cowen has increased its target price for Encompass Health Corp (EHC.N) to $140 from $125. This adjustment reflects an updated outlook from the analyst firm regarding the healthcare company's valuation. The information is sourced from Reuters.
Reinhart Partners LLC. Has $44.01 Million Stock Position in Encompass Health Corporation $EHC
Reinhart Partners LLC. increased its stake in Encompass Health Corporation (NYSE:EHC) by 1.9% in the second quarter, bringing its total holdings to 435,362 shares valued at approximately $44.01 million. Encompass Health reported strong quarterly results, exceeding analyst expectations with $1.55 EPS and $1.60 billion in revenue, and raised its fiscal 2026 EPS guidance. The company also increased its quarterly dividend, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $146.57.
Encompass Health (NYSE: EHC) grows Q2 2026 revenue and EPS
Encompass Health Corporation reported higher Q2 2026 results, with net operating revenues increasing to $1,597.4 million, driven by growth in patient discharges and net patient revenue per discharge. Net income attributable to Encompass Health was $153.9 million, and diluted EPS from continuing operations was $1.55. The company also detailed its liquidity, capital structure, and ongoing expansion efforts, alongside challenges like regulatory compliance and staffing.
ENCOMPASS HEALTH CORP : TRUIST SECURITIES RAISES TARGET PRICE TO $150 FROM $140
Truist Securities has increased its target price for Encompass Health Corp (EHC.N) from $140 to $150. This adjustment signals a more optimistic outlook from the financial firm regarding the company's future stock performance.
Encompass Health Corporation (EHC) Q2 2026 Earnings Call Transcript
Encompass Health Corporation reported strong Q2 2026 results, with revenue up 9.6%, adjusted EBITDA increasing 9.2%, and adjusted EPS rising 10.7%. The company raised its full-year 2026 guidance and highlighted outstanding patient outcomes, increased participation in clinical staff development programs, and continued investment in capacity additions. Management also discussed the repeal of North Carolina's certificate of need law for inpatient rehabilitation care, presenting significant growth opportunities, and the positive early results of their "admit and appeal" strategy for Medicare Advantage denials.
Encompass Health reports results for second quarter 2026
Encompass Health (NYSE: EHC) reported strong results for the second quarter of 2026, with net operating revenue increasing by 9.6% and Adjusted EBITDA growing by 9.2%. The company raised its full-year 2026 guidance and announced an increase in its common stock repurchase authorization to $1 billion. Encompass Health also highlighted its continued expansion, having opened three new hospitals and added 54 beds to existing facilities in the first half of the year.
Compared to Estimates, Encompass Health (EHC) Q2 Earnings: A Look at Key Metrics
Encompass Health (EHC) reported Q2 2026 revenue of $1.6 billion, a 9.6% increase year-over-year, and an EPS of $1.55, up from $1.40. Both figures surpassed analyst estimates, with revenue showing a 1.52% surprise and EPS a 4.73% surprise. Key metrics like net patient revenue per discharge and net operating revenues also exceeded expectations, though the stock has underperformed the S&P 500 recently with a Zacks Rank #4 (Sell).
Encompass Health earnings on deck after strong start to 2026
Encompass Health (EHC) is preparing to release its second-quarter earnings, with analysts anticipating $1.48 EPS and $1.57 billion in revenue, reflecting a strong start to the year. Investors will be closely watching the company's ability to manage an ambitious capacity expansion and maintain operational improvements. The company's recent performance includes a strong first-quarter beat, raised full-year guidance, and a dividend increase, indicating management confidence.
Encompass Health Corp expected to post earnings of $1.48 a share - Earnings Preview
Encompass Health Corp (EHC) is anticipated to report earnings of $1.48 per share, according to a preview from Refinitiv. This news was published on TradingView, highlighting the expected financial performance of the company. The full article is available through a subscription to TradingView's news services.
Earnings To Watch: Encompass Health (EHC) Reports Q2 Results Tomorrow
Encompass Health (EHC) is set to report its Q2 earnings this Wednesday after market close. The company beat revenue expectations last quarter and analysts expect a 7.7% year-on-year revenue growth for Q2. Investors have shown steady interest in the healthcare providers & services segment, with EHC shares up 4.4% in the last month.
